RESEARCH TRIANGLE PARK, N.C. – October 6, 2011 – Quintiles today announced that Steven Skolsky has been appointed Global Head of its Clinical & Data Operations (CDO) unit, the core of the company’s Clinical Development division that monitors the clinical conduct at research sites and collects and manages data from thousands of patients in hundreds of clinical trials conducted around the world.
A 30-year veteran of the biopharmaceutical industry, Skolsky will lead the 5,000-employee CDO unit, which unites Clinical Data Management and Clinical Operations under one umbrella to accelerate data flow and ensure the quality of Quintiles’ data.
Steve’s deep knowledge of the industry and proven leadership capabilities will enable Quintiles to increase the value that we deliver to customers in today’s rapidly changing environment we call the New Health,” said Paula Brown Stafford, President of Clinical Development at Quintiles.
Skolsky previously served as Vice Chairman of the Board and is a current board director for Basilea Pharmaceutica, a Basel, Switzerland-based pharmaceutical company. He also serves as a member of the Board of Directors for Adherex Technologies, a clinical stage oncology company based in Raleigh, N.C. Most recently, he was Principal at Expis Partners, a strategic life science consultancy. He previously served as President and Chief Executive Officer of Sequoia Pharmaceuticals and Chief Executive Officer of Trimeris, Inc., and spent more than 20 years at GlaxoSmithKline in a range of senior leadership roles, including Senior Vice President of Global Clinical Development and Product Strategy.
Biopharma companies are looking for an ally who can bring innovative solutions to the table that increase the speed and quality of clinical research,” said Skolsky. “I am pleased to lead Quintiles’ Clinical & Data Operations unit as we ally with customers to leverage new processes and cutting-edge technologies, like Quintiles Infosario, to transform clinical research and make informed drug development decisions. It is an exciting time in drug development, and I look forward to being a part of Quintiles as we help customers navigate the new landscape.”
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 22,000 engaged professionals in 60 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.